What Remegen does

RemeGen Co., Ltd. (荣昌生物制药（烟台）股份有限公司) is a Chinese biopharmaceutical company founded in 2008 in Yantai, Shandong, that discovers, develops, manufactures, and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology. Its two commercial products are Telitacicept (RC18, brand Tai'ai), the world's first approved BLyS/APRIL dual-target fusion protein with five approved indications in China including systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjögren's disease, and IgA nephropathy; and Disitamab Vedotin (RC48, brand Aidixi), China's first independently developed antibody-drug conjugate (ADC) targeting HER2 with five approved indications spanning gastric cancer, urothelial carcinoma, and breast cancer. The technology foundation consists of four integrated platforms: an antibody/fusion protein platform with hybridoma and display-based screening and 70,000-liter GMP manufacturing capacity; an ADC platform based on proprietary Thiel-bridge site-specific conjugation chemistry; a HiBody bispecific antibody platform; and a PR-ADC payload-recovery platform. R&D operations span Yantai, Beijing, Shanghai, and South San Francisco.

RemeGen monetizes through three revenue streams: domestic commercial product sales reimbursed under China's National Reimbursement Drug List (NRDL), generating 2,271 million yuan in 2025 product sales; outbound licensing of ex-Greater China rights to top-tier global pharmaceutical partners (AbbVie for RC148, Vor Bio for Telitacicept, Pfizer/Seagen for Disitamab Vedotin, Santen for RC28-E), with cumulative potential deal value exceeding $12.6 billion; and future royalty streams from those licensed territories. The company serves patients in China through a direct sales infrastructure of approximately 1,400 medical representatives covering over 2,000 hospitals across autoimmune and oncology specialty departments, supported by medical affairs and KOL engagement programs at major academic conferences (ASCO, ESMO, EULAR, ASCO-GU). RemeGen is dual-listed on the Hong Kong Stock Exchange (09995.HK, since 2020) and the Shanghai STAR Market (688331.SH, since 2022), reported 2025 revenue of 3,251 million yuan (+89% YoY) with 710 million yuan in net profit, and treats patients via its core clinical value proposition of first-in-class or best-in-class targeted biologics in indications previously limited to corticosteroids, broad immunosuppressants, or chemotherapy.

Name

Remegen

Legal name

RemeGen Co., Ltd. (荣昌生物制药（烟台）股份有限公司)

Website

https://remegen.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

RemeGen is a Chinese biopharmaceutical company that develops and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology, anchored by Telitacicept (world's first BLyS/APRIL dual-target fusion protein) and Disitamab Vedotin (China's first independently developed HER2 ADC), distributed through 2,000+ Chinese hospitals and out-licensed globally to partners including AbbVie, Pfizer, Vor Bio, and Santen.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industries

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Antibody drug conjugates
• Biologic therapeutics
• Autoimmune disease treatments
• Oncology biologics
• Fusion protein drugs

Headquarters

HQ city

Yantai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Domestic Commercial Product Sales: RemeGen generates revenue from domestic sales of its approved innovative biologics in China, including Telitacicept (RC18) and Disitamab Vedotin (RC48). Sales are made through hospital procurement channels and reimbursed via the National Reimbursement Drug List (NRDL). In 2025, domestic product sales reached 22.71 billion yuan, up 34% year-over-year, with 2025 full-year revenue of 32.51 billion yuan (+89.36%). The company is profitable with 2025 net profit of 710 million yuan.
2. Outbound Licensing (Milestone Payments and Royalties): RemeGen licenses its proprietary drug candidates to international pharmaceutical partners (AbbVie, Vor Bio, Pfizer/Seagen, Santen) for development and commercialization outside Greater China. The company receives upfront payments, development/regulatory milestones, and tiered royalties on net sales. Key deals include AbbVie for RC148 ($650M upfront, up to $4.95B milestones + royalties), Vor Bio for Telitacicept ($45M upfront + warrants + up to $4B milestones), Pfizer/Seagen for RC48 ($2.6B), and Santen for RC28-E (RMB 250M upfront + milestones).
3. Cumulative Sales and Patient Reach: Cumulative sales of approved products have exceeded 5 billion yuan (RMB), with over 100,000 patients benefiting from treatment. Telitacicept sales in 2025 reached 1.387 billion yuan, growing 41.94% year-over-year with 2.255 million vials sold. Disitamab Vedotin sold 301,900 vials in 2025 (+27.31% YoY).

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

RemeGen is a clinical-stage-to-commercial biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology. Its two commercially marketed products are Telitacicept (Tai'ai®, RC18), a BLyS/APRIL dual-target fusion protein approved for systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjögren's syndrome, and IgA nephropathy, and Disitamab Vedotin (Aidixi®, RC48), a HER2-targeted antibody-drug conjugate approved for gastric cancer, urothelial carcinoma, and breast cancer. Revenue is generated through direct hospital sales in China under NRDL reimbursement and through global out-licensing of pipeline assets to multinational pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

• Telitacicept (泰它西普/泰爱®): World's first innovative dual-target biological medication targeting BLyS and APRIL for autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, Sjögren's syndrome, and IgA nephropathy
• Disitamab Vedotin (维迪西妥单抗/爱地希®)
• RC28
• RC148
• RC88
• RC278

Products and services

• Telitacicept (Tai'ai® / 泰爱®, RC18) World's first BLyS/APRIL dual-target TACI-Fc fusion protein that simultaneously binds and neutralizes B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) cytokines, blocking B-cell abnormal differentiation and maturation through dual pathway inhibition. Approved in China for systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjögren's syndrome, and IgA nephropathy. Used by hospital rheumatologists, nephrologists, and neurologists for patients with B-cell-mediated autoimmune diseases.
• Disitamab Vedotin (Aidixi® / 爱地希®, RC48) China's first independently developed novel antibody-drug conjugate (ADC) targeting HER2, using a novel HER2-targeting antibody with higher affinity and improved internalization combined with an enzymatically cleavable MC-Val-Cit-PAB linker and MMAE payload to enable bystander killing of neighboring tumor cells. Approved in China for HER2-expressing gastric cancer, urothelial carcinoma, and breast cancer, and in development globally (via Pfizer/Seagen license) for HER2-expressing solid tumors.
• RC28 VEGF/FGF dual-target fusion protein simultaneously targeting angiogenesis and fibrosis pathways for treatment of ocular neovascular diseases including diabetic macular edema (DME), wet age-related macular degeneration (wAMD), and diabetic retinopathy (DR). Commercialization rights in Greater China and select Asian countries licensed to Santen Pharmaceutical.
• RC148 PD-1/VEGF bispecific antibody simultaneously targeting PD-1 immune checkpoint and VEGF angiogenesis pathways to activate anti-tumor immune responses and inhibit tumor-driven angiogenesis. In clinical development for solid tumors including non-small cell lung cancer (NSCLC) and colorectal cancer. Global (ex-Greater China) rights licensed to AbbVie.

Quantifiable outcome

• Telitacicept 52-week SRI-4 response rate of 82.6% in systemic lupus erythematosus
• +8 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• AbbVieflagshipStrategic or Co-development Partner · 12 January 2026In January 2026, RemeGen granted AbbVie exclusive rights to develop, manufacture, and commercialize RC148 (PD-1/VEGF bispecific antibody) outside Greater China. RemeGen received $650 million upfront and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments, plus tiered double-digit royalties on net sales. This represents one of the largest China-outbound licensing deals for a bispecific antibody.
• SantencoreStrategic or Co-development Partner · 18 August 2025In August 2025, RemeGen entered an exclusive licensing agreement with Santen Pharmaceutical (China) for RC28-E (VEGF/FGF dual-target fusion protein) in Greater China and select Asian countries (South Korea, Thailand, Vietnam, Singapore, Philippines, Indonesia, Malaysia). RemeGen received RMB 250 million upfront and is eligible for up to RMB 1.045 billion in development/regulatory milestones plus tiered royalties. RemeGen retains global rights outside the licensed territories.
• Vor BioflagshipStrategic or Co-development Partner · 25 June 2025In June 2025, RemeGen out-licensed Telitacicept (RC18) to Vor Bio for development and commercialization outside Greater China. The deal included $45 million upfront, warrants giving a RemeGen subsidiary a 23% stake in Vor, a $175 million private placement, and potential milestones of up to $4 billion plus royalties. Vor Bio is advancing global Phase 3 trials in generalized myasthenia gravis and Sjogren's disease.
• Junshi BiosciencescoreStrategic or Co-development Partner · 1 January 2024RemeGen collaborated with Junshi Biosciences to conduct the RC48-C016 Phase III trial combining disitamab vedotin with toripalimab (Junshi's PD-1 inhibitor) for first-line treatment of HER2-expressing urothelial carcinoma. The combination therapy received NMPA approval in April 2026 and was published in NEJM. This represents a co-development and co-commercialization arrangement in China.
• Pfizer (formerly Seagen)flagshipStrategic or Co-development Partner · 1 August 2021In August 2021, Seagen (subsequently acquired by Pfizer) licensed exclusive rights to develop and commercialize disitamab vedotin (RC48) outside the Asia-Pacific region for up to $2.6 billion in upfront and milestone payments plus tiered royalties. This deal set a record for the largest single-product overseas licensing by a Chinese pharma company at the time.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BeiGene: Chinese dual-listed (NASDAQ: ONC, HKEX: 6160) oncology biotech developing innovative biologics and small molecules including the PD-1 inhibitor tislelizumab. Comparable as a China-originated, dual-listed biotech with global out-licensing and direct commercialization ambitions across oncology and immunology.
• Innovent Biologics: Chinese innovative biologics company (HKEX: 1801) with commercial PD-1 (sintilimab) and a robust ADC and bispecific pipeline. Directly comparable to RemeGen as a China-headquartered developer of innovative biologics with NRDL-driven commercialization and selective out-licensing.
• Akeso: Chinese biotech (HKEX: 9926) specializing in bispecific antibodies, including ivonescimab (PD-1/VEGF). Directly comparable to RemeGen's RC148 program in the PD-1/VEGF bispecific category, with both companies focused on next-generation immuno-oncology biologics.
• Junshi Biosciences: Chinese biotech (HKEX: 1877, SHA: 688180) that developed toripalimab — RemeGen's combination partner for disitamab vedotin. Comparable as a China-headquartered PD-1 developer with NRDL commercialization and selective global partnerships.

Broad incumbents

• Hengrui Medicine: China's largest innovative pharmaceutical company (SHA: 600276) with broad ADC, biologics, and small molecule portfolios. Comparable as a Chinese innovative pharma leader with NRDL-driven commercialization, though operating across many more therapeutic areas than RemeGen.
• Hansoh Pharmaceutical: Chinese innovative pharma company (HKEX: 3692) with biologics and small molecule portfolios across oncology and CNS. Comparable as a NRDL-active Chinese innovative pharma, though with a broader therapeutic footprint than RemeGen.
• AbbVie: Global biopharmaceutical leader (NYSE: ABBV) with blockbuster autoimmune assets (Skyrizi, Rinvoq) and immuno-oncology portfolio. Comparable as a RemeGen licensing partner for RC148 and as a benchmark for autoimmune commercial scale.
• Pfizer: Global biopharmaceutical company (NYSE: PFE) that acquired Seagen, RemeGen's partner for disitamab vedotin ex-Asia-Pacific. Comparable as a global oncology powerhouse with ADC franchise (Padcev) and as a RemeGen commercialization partner.
• AstraZeneca: Global biopharmaceutical company (NASDAQ: AZN) with a major ADC franchise (Enhertu via Daiichi partnership) and significant immuno-oncology portfolio. Comparable as a global ADC and biologics leader whose franchise overlaps with RemeGen's Disitamab Vedotin positioning.

Others

• WuXi Biologics: Global biologics CDMO (HKEX: 2269) providing development and manufacturing services for antibody and biologic drug developers. Comparable as a Chinese-headquartered biologics infrastructure provider relevant to RemeGen's manufacturing and platform strategy, though operating as a service provider rather than a product developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds2 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remegen